两种前列腺素抑制二磷酸腺苷诱导血小板聚集强弱的体外对比

Abstract
Figure/Table
References
Related Citation (4)

Download: PDF (696 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo investigate the inhibitory effects of two types of prostaglandins(epoprostenol sodium and prostaglandin E₁) on adenosine diphosphate (ADP)-induced platelet aggregation in vitro.Methods Platelet suspension was incubated with epoprostenol sodium and prostaglandin E₁ respectively at different concentrations(0, 50, 125, 500 and 2500 ng/ml)before the maximal extent of platelet aggregation was determined at the best ADP concentration and the best incubation time.Results At 20 μM ADP and after incubation of 5 min, the platelet aggregation of both types of prostaglandins induced by ADP was reduced accordingly with the increase of the concentrations of epoprostenol sodium and prostaglandin E₁. The inhibitory rate of platelet aggregation induced by epoprostenol sodium was 19.61%, 48.13%, 88.25%, 93.71%, and 100% respectively,compared with 5.20%, 11.70%, 23.16%, 28.10% and 65.09% respectively for prostaglandin E₁.Conclusions Epoprostenol sodium and prostaglandin E₁ can inhibit ADP-induced platelet aggregation in a concentration-dependent manner in vitro, and the former is more effective.

Key words： epoprostenol sodium prostaglandin E1 adenosine diphosphate platelet aggregation

Received: 02 June 2019

ZTFLH:

R446.11

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XIA Qing
	LI Yi
	LI Wei
	HU Huijing
	CHEN Yun
	RUAN Jingxiong

Cite this article:

XIA Qing,LI Yi,LI Wei等. Comparative study of two prostaglandins inhibiting adenosine diphosphate-induced platelet aggregation in vitro[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2020, 31(3): 195-198.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2020/V31/I3/195

[1]	Weiss H J, Turitto V T. Prostacyclin (Prostaglandin I2, PGI2) inhibits plat-elet adhesion and thrombus formation on subendothelium[J], Blood, 1979, 53(2): 244-250.
[2]	O’Connell C, Amar D, Boucly A, et al. Comparative safety and tolerability of prostacyclins in pulmonary hypertension[J], Drug Saf, 2016, 39(4): 287-294.
[3]	Akagi S, Nakamura K, Matsubara H, et al. Epoprostenol therapy for pulm-onary arterial hypertension[J], Acta Med Okayama, 2015, 69(3): 129-136.
[4]	Chin K M, Badesch D B, Robbins I M, et al. Two formulations of epoprostenol sodium in the trea tment of pulmonary arterial hypertension: PITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), aphase Ⅳ, open-label, randomized study[J]. Am Heart J, 2014, 167(2): 218-225.
[5]	王琳.前列地尔联合甲钴胺治疗糖尿病视网膜病变临床疗效观察[J].临床合理用药,2018, 11(3): 58-59.
[6]	周俊江.探讨前列地尔治疗突发性耳聋的临床应用价值[J]. 江西医药, 2013, 48(12): 1261-1262.
[7]	樊华英,李慧娟,韩俊霞. 前列地尔联合厄贝沙坦治疗对老年糖尿病肾病患者蛋白尿、hs-CRP的效果分析[J]. 中国现代药物应用,2018,12(22): 126-127.
[8]	江思德,肖静,邹耀兵,等. 前列地尔注射液治疗急性脑梗死44例临床疗效研究[J]. 中国药业, 2015, 24(24):31-32.
[9]	李珊珊.硫辛酸与前列地尔联合治疗糖尿病早期微血管病变的临床观察[J]. 药物研究, 2016, (7):78.
[10]	傅桥菲, 陈春林. 前列地尔治疗高血压视网膜病变的临床研究[J].江西医药, 2018, 53(11): 1321-1323.
[11]	方淑贤,郑恒,刘东,等. 穿心莲内酯对二磷酸腺苷诱导血小板聚集的拮抗作用[J]. 医药导报, 2004 23(11):805-806.
[12]	但刚, 罗鸿雁, 江忠勇,等. 不同血小板浓度对血小板聚集率的影响探讨[J]. 西南国防医药, 2016, 26(8):832-834.
[13]	林兆瑛.血小板聚集素(TXA_2)和前列腺环素(PGI_2)[J]. 四川生理科学动态, 1983 (1):9-15.
[14]	Fred V, Victor A, Skrinska, et al. Stability of prostacyclin in human and rabbit whole blood and plasa[J], Thromab Res, 1986,43:379-387.
[15]	内阁莱什.R.帕莱普. 新颖的依前列醇制剂及其制备方法[P].中国专利,公开号:CN 101410119.
[16]	Madelene Lindkvist,Ulrika Fernberg,Liza U. Individual variations in platelet reactivity towards ADP, epinephrine, collagen and nitric oxide, and the association to arterial function in young, healthy adults[J]. Thromb Res, 2019, 174: 5-12.
[17]	翟婷,华声瑜. 血小板ADP受体及其拮抗剂的研究进展[J]. 天津中医药, 2017, 34(4):280-284.